T133

Overview

T133 is an orally active ATP-competitive mTOR inhibitor with an IC 50 of 0.34 nM and a K i of 0.17 nM. T133 suppresses phosphorylation of AKT , S6K1 , and 4EBP1 . T133 inhibits cancer cell proliferation and migration, induces apoptosis , cell cycle arrest, and autophagy . T133 exhibits dose-dependent antitumor efficacy in xenograft mouse models. T133 can be used for the research of cancer , such as gastric cancer and lung cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Ribosomal S6 Kinase (RSK) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-181650
• CAS No.: 3101627-06-6
• Molecular Formula: C21H19N5O5
• Molecular Weight: 421.41
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source